Literature DB >> 9331516

Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold.

J J van Hilten1, E A Wagemans, S F Ghafoerkhan, T van Laar.   

Abstract

We evaluated the responsiveness of tap rate (TR), movement time (MT), and reaction time (RT) to intravenous (i.v.) (n = 10) and subcutaneous (s.c.) (n = 16) administration of apomorphine in patients with Parkinson's disease (PD). In the second part of this study, we evaluated the feasibility of the commonly used 15% TR threshold, above which a patient is considered to be a responder. Compared to MT, TR emerged as the most responsive measure of bradykinesia during both i.v. and s.c. administration of apomorphine. RT showed no response to dopaminergic stimulation. To evaluate the influence of threshold on the number of responsive sessions, we determined the baseline variability of TR by means of the coefficient of variation (CV) in 39 patients with PD. Our results show approximately similar numbers of responsive sessions using the 15% and 2CV threshold. Our findings suggest that a simple repetitive motor task--TR--is more responsive than is the MT task. Finally, the 15% threshold may be considered an adequate threshold for TR in assessment of dopaminergic responsiveness of bradykinesia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331516

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

Authors:  John G Nutt; Kathy A Chung; Nicholas H G Holford
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

2.  Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.

Authors:  Matthew A Brodsky; Byung S Park; John G Nutt
Journal:  Arch Neurol       Date:  2010-01

3.  Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

Authors:  John G Nutt; Steven A Gunzler; Trish Kirchhoff; Penelope Hogarth; Jerry L Weaver; Michael Krams; Brenda Jamerson; Frank S Menniti; Jaren W Landen
Journal:  Mov Disord       Date:  2008-10-15       Impact factor: 10.338

4.  Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.

Authors:  John G Nutt; Carolin Curtze; Amie Hiller; Shannon Anderson; Paul S Larson; Amber D Van Laar; R Mark Richardson; Marin E Thompson; Alexander Sedkov; Mika Leinonen; Bernard Ravina; Krystof S Bankiewicz; Chadwick W Christine
Journal:  Mov Disord       Date:  2020-03-09       Impact factor: 10.338

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.